Press Releases

Date Title and Summary View
Toggle Summary Revance Investor Day Highlights New Neuroscience Indications in Development
- Lead product for treatment of glabellar lines on track to report SAKURA Phase 3 open-label safety results in second half of 2018 - - Initiating Phase 3 pivotal trial for cervical dystonia in current quarter - - Company to add RT002 clinical programs in adult upper limb spasticity and chronic
View HTML
Toggle Summary Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic
View HTML
Toggle Summary Revance to Host Investor Day on April 19, 2018
- Webcast to begin at 12:00pm ET - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will host a live webcast of its
View HTML
Toggle Summary Revance to Participate in the Needham Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York,
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in two upcoming investor conferences.
View HTML
Toggle Summary Revance Releases Fourth Quarter and Full Year 2017 Results
- Announces collaboration and license agreement with Mylan for proposed biosimilar to BOTOX ® - -Cash and investments of approximately $283 million as of December 31, 2017 - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing
View HTML
Toggle Summary Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
View HTML
Toggle Summary Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018
Conference Call Scheduled for Wednesday, February 28, 2018 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2018 Global Healthcare
View HTML
Toggle Summary Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced presentation of clinical data from the company's two pivotal SAKURA Phase 3 trials of
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools